Disruption of FAT10-MAD2 binding inhibits tumor progression

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 49, 2014, Pages E5282-E5291

  Theng, Steven Setiawan ^a,b   Wang, Wei ^b   Mah, Way Champ ^b,c   Chan, Cheryl ^b,c   Zhuo, Jingli ^c   Gao, Yun ^c   Qin, Haina ^b   Lim, Liangzhong ^b   Chong, Samuel S ^a   Song, Jianxing ^b   Lee, Caroline G ^a,b,c,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Aneuploidy; Cancer progression; Chromosomal instability; FAT10; Ubiquitin

Indexed keywords

FAT10 PROTEIN; PROTEIN MAD2; UBIQUITIN; UNCLASSIFIED DRUG; MAD2L1 PROTEIN, HUMAN; PROTEIN BINDING; UBD PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE DISRUPTION; GENE OVEREXPRESSION; HETERONUCLEAR SINGLE QUANTUM COHERENCE; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; PROTON NUCLEAR MAGNETIC RESONANCE; WILD TYPE; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CELL CYCLE; CELL SEPARATION; CHEMICAL STRUCTURE; DISEASE COURSE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HCT116 CELL LINE; MALE; METABOLISM; NEOPLASM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN TERTIARY STRUCTURE; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANIMALS; CELL CYCLE; CELL PROLIFERATION; CELL SEPARATION; CHROMOSOMAL INSTABILITY; DISEASE PROGRESSION; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; MAD2 PROTEINS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; NEOPLASMS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SEQUENCE HOMOLOGY, AMINO ACID; UBIQUITINS;

EID: 84916216378     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1403383111     Document Type: Article

References (36)

1. Schmidtke G, Kalveram B, Groettrup M (2009) Degradation of FAT10 by the 26S proteasome is independent of ubiquitylation but relies on NUB1L. FEBS Lett 583(3):591-594.
2. Rani N, Aichem A, Schmidtke G, Kreft SG, Groettrup M (2012) FAT10 and NUB1L bind to the VWA domain of Rpn10 and Rpn1 to enable proteasome-mediated proteolysis. Nat Commun 3:749.
3. Hipp MS, Kalveram B, Raasi S, Groettrup M, Schmidtke G (2005) FAT10, a ubiquitin-independent signal for proteasomal degradation. Mol Cell Biol 25(9):3483-3491.
4. Liu YC, et al. (1999) A MHC-encoded ubiquitin-like protein (FAT10) binds non-covalently to the spindle assembly checkpoint protein MAD2. Proc Natl Acad Sci USA 96(8):4313-4318.
5. Lee CG, et al. (2003) Expression of the FAT10 gene is highly upregulated in hepatocellular carcinoma and other gastrointestinal and gynecological cancers. Oncogene 22(17):2592-2603.
6. Ebstein F, Lehmann A, Kloetzel PM (2012) The FAT10- and ubiquitin-dependent degradation machineries exhibit common and distinct requirements for MHC class I antigen presentation. Cell Mol Life Sci 69(14):2443-2454.
7. Ren J, Wang Y, Gao Y, Mehta SB, Lee CG (2011) FAT10 mediates the effect of TNF-α in inducing chromosomal instability. J Cell Sci 124(Pt 21):3665-3675.
8. Lukasiak S, et al. (2008) Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon. Oncogene 27(46):6068-6074.
9. Gao Y, et al. (2013) FAT10, an Ubiquitin-like Protein, Confers Malignant Properties in Non-tumorigenic and Tumorigenic Cells. Carcinogenesis 35(4):923-34.
10. Qing X, French BA, Oliva J, French SW (2011) Increased expression of FAT10 in colon benign, premalignant and malignant epithelial neoplasms. Exp Mol Pathol 90(1): 51-54.
11. Yan DW, et al. (2010) Ubiquitin D is correlated with colon cancer progression and predicts recurrence for stage II-III disease after curative surgery. Br J Cancer 103(7): 961-969.
12. Ren J, et al. (2006) FAT10 plays a role in the regulation of chromosomal stability. J Biol Chem 281(16):11413-11421.
13. Holland AJ, Cleveland DW (2009) Boveri revisited: Chromosomal instability, aneuploidy and tumorigenesis. Nat Rev Mol Cell Biol 10(7):478-487.
14. Kops GJ, Weaver BA, Cleveland DW (2005) On the road to cancer: Aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5(10):773-785.
15. Gavin JM, et al. (2012) Mechanistic studies on activation of ubiquitin and di-ubiquitin-like protein, FAT10, by ubiquitin-like modifier activating enzyme 6, Uba6. J Biol Chem 287(19):15512-15522.
16. Kalveram B, Schmidtke G, Groettrup M (2008) The ubiquitin-like modifier FAT10 interacts with HDAC6 and localizes to aggresomes under proteasome inhibition. J Cell Sci 121(Pt 24):4079-4088.
17. Aichem A, et al. (2012) The proteomic analysis of endogenous FAT10 substrates identifies p62/SQSTM1 as a substrate of FAT10ylation. J Cell Sci 125(Pt 19):4576-4585.
18. Li T, et al. (2011) FAT10 modifies p53 and upregulates its transcriptional activity. Arch Biochem Biophys 509(2):164-169.
19. Cornilescu G, Delaglio F, Bax A (1999) Protein backbone angle restraints from searching a database for chemical shift and sequence homology. J Biomol NMR 13(3):289-302.
20. Güntert P (2004) Automated NMR structure calculation with CYANA. Methods Mol Biol 278:353-378.
21. Christen M, et al. (2005) The GROMOS software for biomolecular simulation: GROMOS05. J Comput Chem 26(16):1719-1751.
22. Qin H, et al. (2010) Structural characterization of the EphA4-Ephrin-B2 complex reveals new features enabling Eph-ephrin binding promiscuity. J Biol Chem 285(1):644-654.
23. Komander D, et al. (2009) Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep 10(5):466-473.
24. Qin H, Shi J, Noberini R, Pasquale EB, Song J (2008) Crystal structure and NMR binding reveal that two small molecule antagonists target the high affinity ephrin-binding channel of the EphA4 receptor. J Biol Chem 283(43):29473-29484.
25. Williamson MP (2013) Using chemical shift perturbation to characterise ligand binding. Prog Nucl Magn Reson Spectrosc 73:1-16.
26. Michel L, et al. (2004) Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc Natl Acad Sci USA 101(13):4459-4464.
27. Tapia C, et al. (2006) Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol 30(1):83-89.
28. Wagenaar-Miller RA, Gorden L, Matrisian LM (2004) Matrix metalloproteinases in colorectal cancer: Is it worth talking about? Cancer Metastasis Rev 23(1-2):119-135.
29. Liu L, et al. (2014) As an independent prognostic factor, FAT10 promotes hepatitis B virus-related hepatocellular carcinoma progression via Akt/GSK3beta pathway. Oncogene 33(7):909-920.
30. Merbl Y, Refour P, Patel H, Springer M, Kirschner MW (2013) Profiling of ubiquitin-like modifications reveals features of mitotic control. Cell 152(5):1160-1172.
31. Yu H (2006) Structural activation of Mad2 in the mitotic spindle checkpoint: The two-state Mad2 model versus the Mad2 template model. J Cell Biol 173(2):153-157.
32. Michel LS, et al. (2001) MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 409(6818):355-359.
33. Sotillo R, et al. (2007) Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 11(1):9-23.
34. Wang L, et al. (2010) Depression of MAD2 inhibits apoptosis and increases proliferation and multidrug resistance in gastric cancer cells by regulating the activation of phosphorylated survivin. Tumour biol 31(3):225-232.
35. Schvartzman JM, Duijf PH, Sotillo R, Coker C, Benezra R (2011) Mad2 is a critical mediator of the chromosome instability observed upon Rb and p53 pathway inhibition. Cancer Cell 19(6):701-714.
36. Prencipe M, et al. (2009) Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro. Br J Cancer 101(11):1900-1908.